Chung, Kuei-Pin <br/><br/>
Favorable response to gefitinib treatment of lung adenocarcinoma with coexisting germline and somatic epidermal growth factor receptor mutations.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Dec 2010 
 - e701-3 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2010.28.6260  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Aged<br/>Antineoplastic Agents--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Base Sequence<br/>Chemotherapy, Adjuvant--methods<br/>Cholecystitis--complications<br/>Cisplatin--administration & dosage<br/>Combined Modality Therapy<br/>DNA Mutational Analysis<br/>Female<br/>Gefitinib<br/>Genes, erbB-1<br/>Genetic Predisposition to Disease<br/>Humans<br/>Incidental Findings<br/>Lung Neoplasms--drug therapy<br/>Mutation<br/>Neoplasm Staging<br/>Pedigree<br/>Pneumonectomy<br/>Quinazolines--therapeutic use<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Vinblastine--administration & dosage<br/>Vinorelbine